8.19
前日終値:
$7.78
開ける:
$7.74
24時間の取引高:
574.57K
Relative Volume:
1.42
時価総額:
$151.74M
収益:
$1.54M
当期純損益:
$-84.53M
株価収益率:
-1.4085
EPS:
-5.8145
ネットキャッシュフロー:
$-73.65M
1週間 パフォーマンス:
+8.33%
1か月 パフォーマンス:
-28.35%
6か月 パフォーマンス:
-15.57%
1年 パフォーマンス:
-10.69%
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
名前
Corbus Pharmaceuticals Holdings Inc
セクター
電話
617-963-0103
住所
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
8.19 | 144.15M | 1.54M | -84.53M | -73.65M | -5.8145 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.93 | 112.95B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
612.14 | 64.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
893.52 | 55.90B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
282.85 | 38.64B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
153.87 | 31.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-30 | 再開されました | B. Riley Securities | Buy |
| 2025-02-28 | 開始されました | William Blair | Outperform |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | 開始されました | Wedbush | Outperform |
| 2024-07-22 | 再開されました | H.C. Wainwright | Buy |
| 2024-06-26 | 開始されました | B. Riley Securities | Buy |
| 2024-06-03 | 繰り返されました | Oppenheimer | Outperform |
| 2024-05-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-08 | ダウングレード | BTIG Research | Buy → Neutral |
| 2020-09-08 | ダウングレード | Jefferies | Buy → Hold |
| 2020-09-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-03-26 | 開始されました | Nomura | Buy |
| 2019-04-05 | 開始されました | Jefferies | Buy |
| 2019-03-20 | 開始されました | Oppenheimer | Outperform |
| 2019-01-11 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 開始されました | H.C. Wainwright | Buy |
| 2018-12-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2018-10-24 | 開始されました | B. Riley FBR | Buy |
| 2018-01-19 | 開始されました | Raymond James | Outperform |
| 2017-12-14 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 繰り返されました | Noble Financial | Buy |
| 2017-09-29 | 再開されました | Noble Financial | Buy |
| 2017-03-30 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2016-11-11 | 繰り返されました | Noble Financial | Buy |
すべてを表示
Corbus Pharmaceuticals Holdings Inc (CRBP) 最新ニュース
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals (CRBP) director sells 2,026 shares under 10b5-1 plan - Stock Titan
Corbus (NASDAQ: CRBP) director sells 2,412 shares under 10b5-1 plan - Stock Titan
Corbus (CRBP) director Jenkins sells 4,800 shares in Rule 10b5-1 trade - Stock Titan
Corbus Pharmaceuticals teases cancer, obesity data as key clinical readouts near - MSN
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals targets HPV-linked head and neck cancer with CRB-701 study - MSN
Corbus Pharmaceuticals Teases Cancer, Obesity Data as Key Clinical Readouts Near - Yahoo Finance
Liquidity Mapping Around (CRBP) Price Events - Stock Traders Daily
Insider Spends US$101k Buying More Shares In Corbus Pharmaceuticals Holdings - simplywall.st
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
CRBP: Lead oncology and obesity assets advance with pivotal data and strong financial runway - TradingView
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
CRBP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Corbus Pharmaceuticals CBO Nishant Saxena buys $101,218 in stock By Investing.com - Investing.com Australia
Corbus Pharmaceuticals CBO Nishant Saxena buys $101,218 in stock - Investing.com
Corbus (CRBP) Chief Business Officer buys 13,500 shares in open market - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Oppenheimer Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
A Quick Look at Today's Ratings for Corbus Pharmaceuticals(CRBP.US), With a Forecast Between $40 to $54 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study - Yahoo Finance
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price Today & Analysis - Gotrade
CRBP Q1 2026 Earnings: Narrower Loss Misses on Thin Volume; No Revenue YetWeak Earnings Momentum - thelegaladvocate.com
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Why (CRBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
RBC Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
TNXP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRBP Maintained by Wedbush -- Price Target Lowered to $30 - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Corbus Pharmaceuticals: I'd Preach Caution After Selloff On Latest Data Drop (NASDAQ:CRBP) - Seeking Alpha
LifeSci Capital Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Wedbush Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $30 - Moomoo
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Falls on Reports of Adverse Events in Tumor-Treatment Study - Moomoo
Corbus Pharmaceuticals (CRBP) Analyst Sees Mispriced Weakness - GuruFocus
Corbus Pharmaceuticals (CRBP) Reports Promising Data on CRB-701 Trial - GuruFocus
Corbus Pharmaceuticals Stock (CRBP) Opinions on Updated CRB-701 Cancer Data Release - Quiver Quantitative
CRBP Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
CRB-701 Phase 1/2 data outlines next steps, Corbus Pharmaceuticals Holdings, Inc. - Traders Union
Corbus Pharma (CRBP) Faces Premarket Decline Following Phase 1/2 Trial Data - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCOSlideshow (NASDAQ:CRBP) 2026-05-26 - Seeking Alpha
Corbus Pharmaceuticals stock falls on trial data release By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals stock falls on trial data release - Investing.com
CRB-701 data advances Corbus (NASDAQ: CRBP) OPSCC and cervical plans - Stock Titan
Corbus Pharmaceuticals Holdings Inc (CRBP) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):